{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-060850","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.836902+00:00","generated_at":"2026-06-15T01:16:13.624894+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Outlook Therapeutics reports Q2 net loss $6.7M; PDUFA date Aug 29 for ONS-5010","bullets":["Net loss $6.7M ($0.03/sh) vs $19.7M ($0.09) in prior-year Q2.","Cash $43.7M as of March 31, 2023; expects to fund ops through potential approval in Q3/Q4 2023.","PDUFA goal date Aug 29, 2023 for ONS-5010 (bevacizumab) for wet AMD.","Pre-launch commercial activities ongoing; partnership with AmerisourceBergen for distribution.","MAA for ONS-5010 under EU review; CHMP decision expected early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-060850","json":"https://secwatch.observer/filing/0001104659-23-060850.json","markdown":"https://secwatch.observer/filing/0001104659-23-060850.md","text":"https://secwatch.observer/filing/0001104659-23-060850.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465923060850/0001104659-23-060850-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465923060850/tm2315802d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:16:13.624894+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5fb2ff5607f75e74808369088a1ae0e7b328bfc9","claim":"Outlook Therapeutics, Inc. reported financial results for second fiscal quarter ended March 31, 2023.","evidence_excerpt":"On May 15, 2023, Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its second fiscal quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465923060850/0001104659-23-060850-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second fiscal quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}